Skip to main content

Table 5 Molecular markers of resistance genotypes for treatment failures observed during therapeutic efficacy monitoring in Angola, 2015

From: Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015

Marker n (%)
Benguela Zaire
ASAQ AL AL DP
n = 7 n = 7 n = 1 n = 7 n = 7 n = 1 n = 1 n = 3 n = 12 n = 12 n = 8 n = 8 n = 14 n = 14 n = 1 n = 1
Reinf day 0 Reinf day failure ETF Reinf day 0 Reinf day failure Recr day 0 Recr day failure ETF Reinf day 0 Reinf day failure Recr day 0 Recr day failure Reinf day 0 Reinf day failure Recr day 0 Recr day failure
K13
 Wildtype 7 (100) 7 (100) 1 (100) 7 (100) 7 (100) 1 (100) 1 (100) 3 (100) 12 (100) 12 (100) 8 (100) 8 (100) 14 (100) 14 (100) 1 (100) 1 (100)
cytB
 Wildtype 7 (100) 7 (100) 1 (100) 7 (100) 7 (100) 1 (100) 1 (100) 3 (100) 12 (100) 12 (100) 8 (100) 8 (100) 14 (100) 14 (100) 1 (100) 1 (100)
pfmdr1 a
 NYD 5 (71) 5 (71) 1 (100) 5 (71) 5 (71) 1 (33) 7 (58) 7 (58) 5 (62) 5 (62) 7 (50) 8 (57)
 NFD 1 (14) 1 (14) 2 (29) 2 (29) 1 (100) 1 (100) 3 (25) 5 (42) 3 (38) 3 (38) 5 (36) 4 (29) 1 (100) 1 (100)
 YFD 1 (7) 1 (7)
 YYD 1 (14) 2 (67) 2 (17) 1 (7) 1 (7)
 YYY 1 (14)
  1. In addition to the asynonymous mutations listed in the table, the following synonomous mutations were also observed: pfmdr1 G102G (2 instances), pfmdr1 T1069T (15), pfmdr1 S1137S (1), cytB A295A (1), K13 P553P (1), K13 T535T (2)
  2. ETF early treatment failure, Reinf reinfection, Recr recrudescence, ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
  3. a pfmdr1 haplotype classified according to animo acids at positions 86, 184, and 1246